Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Archives

You are currently viewing the 2004 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: ZOFRAN PRESERVATIVE FREE

« Back to Dashboard
Zofran Preservative Free is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier.

The generic ingredient in ZOFRAN PRESERVATIVE FREE is ondansetron hydrochloride. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. There are two tentative approvals for this compound. Additional details are available on the ondansetron hydrochloride profile page.

Summary for Tradename: ZOFRAN PRESERVATIVE FREE

Patents:3
Applicants:1
NDAs:1
Suppliers: see list1

Pharmacology for Tradename: ZOFRAN PRESERVATIVE FREE

Clinical Trials for: ZOFRAN PRESERVATIVE FREE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Glaxosmithkline
ZOFRAN PRESERVATIVE FREE
ondansetron hydrochloride
INJECTABLE; INJECTION020007-003Dec 10, 1993RXYes4,695,578*PED<disabled><disabled>
Glaxosmithkline
ZOFRAN PRESERVATIVE FREE
ondansetron hydrochloride
INJECTABLE; INJECTION020007-003Dec 10, 1993RXYes4,753,789*PED<disabled><disabled>
Glaxosmithkline
ZOFRAN PRESERVATIVE FREE
ondansetron hydrochloride
INJECTABLE; INJECTION020007-003Dec 10, 1993RXYes5,578,628*PED<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ZOFRAN PRESERVATIVE FREE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,929,632 Medicaments<disabled in preview>
5,578,632 Medicaments for the treatment of gastrointestinal dysfunction<disabled in preview>
6,569,883 Medicaments<disabled in preview>
5,240,954 Medicaments<disabled in preview>
5,922,749 Medicaments for treating nausea and vomiting<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc